Key Findings on the Efficacy and Safety of Testosterone Therapy from Two Large Randomized Trials

Clicks: 82
ID: 329855
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #18 of 417 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 417 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Context Despite widespread use of testosterone therapy, its efficacy and safety in men with age-related low testosterone remain a matter of debate. Elucidating its benefits and risks is essential for clinical decision-making. Evidence Acquisition This narrative review synthesizes evidence from two large randomized controlled trials: the Testosterone Trials (T Trials) and the TRAVERSE trial. The T Trials assessed the efficacy of testosterone treatment in men ≥65 years with age-related syndromic androgen deficiency. The TRAVERSE trial assessed long-term cardiovascular safety of testosterone therapy in men aged 45–80 years with high cardiovascular risk. Prostate and skeletal safety were also assessed. We critically evaluate the design, outcomes, and shortcomings of these trials. Evidence Synthesis In the T Trials, testosterone therapy, compared with placebo, improved sexual function and mood, but not physical function, vitality, or cognitive function. In the TRAVERSE trial, testosterone therapy was noninferior to placebo with respect to major adverse cardiovascular events (MACE). Prostate-related events were comparable between groups, but fracture rates were unexpectedly higher in the testosterone group. Conclusions Results from the T Trials and TRAVERSE trial showed that testosterone therapy improves sexual function and mood but not vitality or physical function. Importantly, it did not increase MACE in men at high risk of cardiovascular disease. Based on these data, treatment with testosterone could be considered in middle-aged and older men with syndromic androgen deficiency to target symptoms where it has demonstrated efficacy, whereas therapies other than testosterone might be warranted for outcomes that were not improved by testosterone.
Reference Key
openalex_W7214457898 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Milena Braga, Shehzad Basaria
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag397
URL
https://doi.org/10.1210/clinem/dgag397
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.